Cargando…

Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies

BACKGROUND: Uric acid has antioxidant effects on neurons. Abnormally high levels of uric acid are, however, associated with gout. Previous studies have suggested that high levels of uric acid (and the presence of gout) may exert a protective effect against the risk of developing some neurological di...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakpoor, Julia, Seminog, Olena O, Ramagopalan, Sreeram V, Goldacre, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355134/
https://www.ncbi.nlm.nih.gov/pubmed/25884318
http://dx.doi.org/10.1186/s12883-015-0273-9
_version_ 1782360827018346496
author Pakpoor, Julia
Seminog, Olena O
Ramagopalan, Sreeram V
Goldacre, Michael J
author_facet Pakpoor, Julia
Seminog, Olena O
Ramagopalan, Sreeram V
Goldacre, Michael J
author_sort Pakpoor, Julia
collection PubMed
description BACKGROUND: Uric acid has antioxidant effects on neurons. Abnormally high levels of uric acid are, however, associated with gout. Previous studies have suggested that high levels of uric acid (and the presence of gout) may exert a protective effect against the risk of developing some neurological diseases. We aimed to investigate this hypothesis in a large database of hospital admissions in England. METHODS: We analysed a database of linked statistical records of hospital admissions and death registrations in England (1999–2012). A cohort of people with gout was constructed and followed for development of multiple sclerosis (MS), Parkinson’s disease (PD) or motor neuron disease (MND). Then, conversely, cohorts of all people in the database with MS, PD or MND were constructed and followed for subsequent gout. Rate ratios (RRs) were determined, comparing these cohorts with people in a reference cohort. RESULTS: In the gout cohort, we observed a modest elevation of the overall risk of subsequent MS, PD and MND (respectively, RR = 1.27 (95% confidence interval 1.03-1.55), 1.11 (1.05-1.17) and 1.28 (1.11-1.48) which was largely attributable to an increased risk observed in the early years after hospitalisation for gout. The increased risk of neurological disease did not remain after 5 years. In the cohorts of people with MS or PD, there was a significantly reduced risk of subsequent gout admission (RR = 0.79 (0.69-0.89) and 0.83 (0.79-0.87), respectively). This inverse association was sustained over time. There was also a reduced risk of MND following gout which only emerged more than five years following initial gout admission (RR at 5+ years 0.35 (0.15-0.68)). CONCLUSIONS: This study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND. Our observations do not support this hypothesis. However, when the order was reversed, and we retrospectively followed up patients with MS, PD and MND for a number of years, we found a statistically significant deficit of gout. This suggests that there is relationship between some aspects of these neurodegenerative diseases and metabolism of uric acid.
format Online
Article
Text
id pubmed-4355134
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43551342015-03-12 Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies Pakpoor, Julia Seminog, Olena O Ramagopalan, Sreeram V Goldacre, Michael J BMC Neurol Research Article BACKGROUND: Uric acid has antioxidant effects on neurons. Abnormally high levels of uric acid are, however, associated with gout. Previous studies have suggested that high levels of uric acid (and the presence of gout) may exert a protective effect against the risk of developing some neurological diseases. We aimed to investigate this hypothesis in a large database of hospital admissions in England. METHODS: We analysed a database of linked statistical records of hospital admissions and death registrations in England (1999–2012). A cohort of people with gout was constructed and followed for development of multiple sclerosis (MS), Parkinson’s disease (PD) or motor neuron disease (MND). Then, conversely, cohorts of all people in the database with MS, PD or MND were constructed and followed for subsequent gout. Rate ratios (RRs) were determined, comparing these cohorts with people in a reference cohort. RESULTS: In the gout cohort, we observed a modest elevation of the overall risk of subsequent MS, PD and MND (respectively, RR = 1.27 (95% confidence interval 1.03-1.55), 1.11 (1.05-1.17) and 1.28 (1.11-1.48) which was largely attributable to an increased risk observed in the early years after hospitalisation for gout. The increased risk of neurological disease did not remain after 5 years. In the cohorts of people with MS or PD, there was a significantly reduced risk of subsequent gout admission (RR = 0.79 (0.69-0.89) and 0.83 (0.79-0.87), respectively). This inverse association was sustained over time. There was also a reduced risk of MND following gout which only emerged more than five years following initial gout admission (RR at 5+ years 0.35 (0.15-0.68)). CONCLUSIONS: This study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND. Our observations do not support this hypothesis. However, when the order was reversed, and we retrospectively followed up patients with MS, PD and MND for a number of years, we found a statistically significant deficit of gout. This suggests that there is relationship between some aspects of these neurodegenerative diseases and metabolism of uric acid. BioMed Central 2015-02-28 /pmc/articles/PMC4355134/ /pubmed/25884318 http://dx.doi.org/10.1186/s12883-015-0273-9 Text en © Pakpoor et al.; licensee BioMed Central. . 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pakpoor, Julia
Seminog, Olena O
Ramagopalan, Sreeram V
Goldacre, Michael J
Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies
title Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies
title_full Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies
title_fullStr Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies
title_full_unstemmed Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies
title_short Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies
title_sort clinical associations between gout and multiple sclerosis, parkinson’s disease and motor neuron disease: record-linkage studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355134/
https://www.ncbi.nlm.nih.gov/pubmed/25884318
http://dx.doi.org/10.1186/s12883-015-0273-9
work_keys_str_mv AT pakpoorjulia clinicalassociationsbetweengoutandmultiplesclerosisparkinsonsdiseaseandmotorneurondiseaserecordlinkagestudies
AT seminogolenao clinicalassociationsbetweengoutandmultiplesclerosisparkinsonsdiseaseandmotorneurondiseaserecordlinkagestudies
AT ramagopalansreeramv clinicalassociationsbetweengoutandmultiplesclerosisparkinsonsdiseaseandmotorneurondiseaserecordlinkagestudies
AT goldacremichaelj clinicalassociationsbetweengoutandmultiplesclerosisparkinsonsdiseaseandmotorneurondiseaserecordlinkagestudies